Offices:
Stockholm
Investors:
we tracked 5 investors
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Total investments received (USD) - we tracked 2 transactions
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
Companies with similar profile to Modus Therapeutics:
| Company | Criteria |
|---|
 Asarina Pharma55% | - Similar verticals: Health services
- Similar business models: B2B
- At least one vc investor: Rosetta Capital
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| BoneSupport 45% | - Similar verticals: Health services
- Similar business models: B2B
- At least one vc investor: HealthCap
- Total raised in a similar range: 10M+ USD
|
| OxThera 44% | - Similar business models: B2B
- At least one vc investor: HealthCap
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
 NMD Pharma43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| AMRA 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| ITBMed 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
 Synoste Oy43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| BC Platforms 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Blueprint Genetics 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Valkee 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Irras 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Acarix 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Forendo Pharma 43% | - Similar verticals: Health services
- Similar business models: B2B
- At least one other investor: Karolinska Development
- Total raised in a similar range: 10M+ USD
|
 Oncoinvent43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Glucostratus (Mendor) 43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
- Minim one investor from outside Scandinavia: Yes
|
| Scint-X 35% | - Similar verticals: Health services
- Similar business models: B2B
- At least one vc investor: Praktikerinvest
|
| Min Doktor 34% | - Similar verticals: Health services
- At least one vc investor: HealthCap
- Total raised in a similar range: 10M+ USD
|
| Doctrin 34% | - Similar verticals: Health services
- At least one vc investor: HealthCap
- Total raised in a similar range: 10M+ USD
|
| Vaccibody 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: 10M+ USD
|
| Prediktor 33% | - Similar verticals: Health services
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
